iPSC-derived hepatic cells for efficacy and toxicology screening

Phenotypically and mechanistically relevant wild-type and disease modeled cells produced at scale for reproducible human data

Discover More

Highly characterised and mature Hepatocytes, Stellate Cells & Intestinal Organoids for Research

Advanced Human-Derived Models for Metabolic Disease Research

Our MASLD, Hepatic Stellates, and Intestinal Organoid models provide physiologically relevant, human-derived platforms for studying metabolic diseases. These advanced in vitro systems enable precise disease modeling, drug screening, and mechanistic insights, accelerating the development of targeted therapies.

MASLD

MASLD model represents an optimized cell platform for drug discovery applications and a principal tool for elucidating the underlying mechanisms of the disease...

Learn more

Hepatic Stellate Cells

DefiniGEN have generated the first commercially available iPSC-derived HSCs. The liver is an organ of crucial importance, playing a central role in metabolism, detoxification...

Learn more

Intestinal Organoids

DefiniGEN's iPSC-derived intestinal organoids provide a unique in vitro system to model the human intestine. DefiniGEN’s iPSC-derived intestinal organoids...

Learn more

Cutting-Edge Monogenic Disease Models for Drug Discovery and Disease modeling

We offer several monogenic disease models including A1ATD, Urea Cycle Disorders, and Wilson’s Disease that enable accurate disease modeling, efficacy and mechanistic studies, driving innovation in therapeutic development.

A1ATD

DefiniGEN provide disease modeled alpha-1 antitrypsin deficiency hepatocytes which are highly functional patient-derived or CRISPR edited wild-type cells...

Learn more

Wilson’s Disease

DefiniGEN have created Wilson’s disease model hepatocytes for the evaluation of therapeutic candidates. Wilson’s disease is an autosomal-recessive disorder of the ATP7B gene...

Learn more

Urea Cycle Disorder

Ornithine transcarbamylase (OTC) deficiency is an inherited, X-linked, recessive metabolic disorder and, currently, the most common UCD with a prevalence of one in 60-70,000 in humans...

Learn more

DefiniGEN is a specialized CRO

We focus on delivering liver and metabolic disease models that overcome the drawbacks of traditional models

Highly Predictive

Ulti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function

Scalable

DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocytes with field leading purity, maturity and functionality

Optimized Bioassay Development

Optimized bioassays that can accurately evaluate compound potency, efficacy and toxicology

Scientific expertise

5/10

5 out of the top 10 pharmaceutical companies work with us. Our models are also used by biotechnology companies of all sizes, research institutions and Contract Research Organisations

Peer-reviewed publications featuring our iPSC-derived hepatocytes, Ulti-HEP

5 in-house validated disease models ready for screening

13 years of supporting R&D with our innovative, proprietary iPSC endodermal protocols

The latest from DefiniGEN

Exhibiting

Society of Toxicology

16th-20th March 2025 | Florida, United States

blog

Featured blog

Overcoming the Bottleneck in Drug Discovery: How iPSC-Derived Hepatocytes Improve Preclinical Testing

Read blog

Featured resource

iPSC-derived hepatocytes accurately recapitulate population diversity in alpha-1-antitrypsin deficiency and offer a novel in vitro model for large-scale drug efficacy screening studies...

View resource

Advance your scientific discoveries with our tailored disease modeling products and services

Applications

Cell Products